Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs.
The acyloxyalkyl derivatives of a model anti-HBV dinucleotide were synthesized and evaluated as orally bioavailable prodrugs. Our studies have led to the identification of the first orally bioavailable dinucleotide prodrugs for further therapeutic development against the hepatitis B virus (HBV).
Coughlin
John E
JE
Spring Bank Pharmaceuticals Inc., Milford, MA, United States.
Padmanabhan
Seetharamaiyer
S
Zhang
Guangrong
G
Kirk
Cassandra J
CJ
Govardhan
Chandrika P
CP
Korba
Brent E
BE
O'Loughlin
Kathleen
K
Green
Carol E
CE
Mirsalis
Jon
J
Morrey
John D
JD
Iyer
Radhakrishnan P
RP
D000284:Administration, Oral; D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000627:therapeutic use; D002460:Cell Line; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000235:genetics*; D006801:Humans; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D009711:Nucleotides / Q000138:chemical synthesis / Q000737:chemistry* / Q000627:therapeutic use; D011355:Prodrugs / Q000138:chemical synthesis / Q000737:chemistry* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley
D000998:Antiviral Agents; D009711:Nucleotides; D011355:Prodrugs